Cite
HARVARD Citation
Arciero, V. et al. (2022). Real-world cost-effectiveness of first-line gemcitabine + nab-paclitaxel versus FOLFIRINOX in patients with advanced pancreatic cancer. JNCI cancer spectrum. 6 (4), p. . [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Arciero, V. et al. (2022). Real-world cost-effectiveness of first-line gemcitabine + nab-paclitaxel versus FOLFIRINOX in patients with advanced pancreatic cancer. JNCI cancer spectrum. 6 (4), p. . [Online].